Cytokeratin 5/14, 2X


SKU: 3026 Categories: , ,

Cytokeratin 5/14 Cocktail, 2X is being discontinued. We will continue to offer these products until 06/30/16 or until current inventory is depleted, whichever occurs first. Biocare does offer Cytokeratin 5/14 Cocktail, catalog numbers ACI3025 & API3025 as a substitute.

CK5 [XM26] has been shown to have positive reactivity for CK5 protein and lack of reactivity for CK6 protein by ELISA. CK5 is distributed in many non-keratinizing stratified squamous epithelia such as tongue mucosa, basal epithelia, hair follicles, and trachea, as well as basal cells in prostate glands and myoepithelial cells in mammary glands. CK5 is also expressed in most epithelial and biphasic mesotheliomas. CK5 has been noted in the majority of lung squamous cell carcinoma and is expressed in luminal Type B breast cancers (triple negative).
CK14 is a human intermediate filament protein of 50 kDa. CK14 can be used to distinguish stratified epithelial cells from simple epithelial cells. It is expressed in basal epithelium in prostate and myoepithelium in normal breast. CK14 is a useful marker in the differential diagnosis of squamous cell carcinoma with poor clinical outcome. CK14 is also expressed in luminal Type B breast cancers, similar to CK5. The CK5/CK14 monoclonal antibodies have been shown to be superior to CK5/6 and 34betaE12. Cytokeratin 5/14, 2X may be used to identify basal cells in prostate and myoepithelium cells in breast cancer. Sporadic loss of CK5/14 epithelium staining, along with p63, typically occurs in prostatic intraepithelial neoplasia (PIN), with nearly complete loss in prostate cancer. Additionally, CK5/CK14 + AMACR (P504S) may be added to the panel of antibodies used to assess neoplasia in prostate biopsies. A combination comprised of CK5/CK14 + p63 + P504S has become the standard care for PIN and prostate cancer diagnosis in many histopathology laboratories.
Additionally, studies have shown that CK5/14-positive sporadic breast cancers arise from glandularly committed progenitor cells and represent about 9% of sporadic invasive ductal breast cancers and 78% of BRCA1-associated tumors.

Intended Use


Species Reactivity



Mouse Monoclonal


XM26 (CK5) + LL002 (CK14)


IgG1, kappa (CK5) + IgG3 (CK14)


CK5 + CK14



Positive Control

Normal prostate

1. Abrahams NA, et al. Validation of cytokeratin 5/6 as an effective substitute for keratin 903 in the differentiation of benign from malignant glands in prostate needle biopsies. Histopathology. 2002 Jul;41(1):35-41.
2. Shah RB, et al. Comparison of the basal cell-specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer. Am J Surg Pathol. 2002 Sep;26(9):1161-8.
3. Bhargava R, et al. CK5 is more sensitive than CK5/6 in identifying the “basal-like” phenotype of breast carcinoma. Am J Clin Pathol. 2008 Nov;130(5):724-30.
4. Reis-Filho JS, et al. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray. Virchows Arch. 2003 Aug;443(2):122-32.
5. Laakso M, et al. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol. 2005 Oct;18(10):1321-8.
6. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
7. Clinical and Laboratory Standards Institute (CLSI). Protection of Laboratory Workers from Occupationally Acquired Infections; Approved guideline-Third Edition CLSI document M29-A3 Wayne, PA 2005.


There are no reviews yet.

Be the first to review “Cytokeratin 5/14, 2X”